Gwen A Melincoff - Net Worth and Insider Trading

Gwen A Melincoff Net Worth

The estimated net worth of Gwen A Melincoff is at least $38,226 dollars as of 2024-11-13. Gwen A Melincoff is the Director of Soleno Therapeutics Inc and owns about 667 shares of Soleno Therapeutics Inc (SLNO) stock worth over $38,226. Details can be seen in Gwen A Melincoff's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gwen A Melincoff has not made any transactions after 2019-11-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Gwen A Melincoff

Gwen A Melincoff Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gwen A Melincoff owns 5 companies in total, including Collegium Pharmaceutical Inc (COLL) , Soleno Therapeutics Inc (SLNO) , and Protalix BioTherapeutics Inc (PLX) among others .

Click here to see the complete history of Gwen A Melincoff’s form 4 insider trades.

Insider Ownership Summary of Gwen A Melincoff

Ticker	Comapny	Transaction Date	Type of Owner
COLL	Collegium Pharmaceutical Inc	2022-05-19	director
SLNO	Soleno Therapeutics Inc	2019-11-19	director
PLX	Protalix BioTherapeutics Inc	2020-01-01	director
		2016-11-01	director
		2021-03-17	director

Gwen A Melincoff Latest Holdings Summary

Gwen A Melincoff currently owns a total of 1 stock. Gwen A Melincoff owns 667 shares of Soleno Therapeutics Inc (SLNO) as of November 19, 2019, with a value of $38,226.

Latest Holdings of Gwen A Melincoff

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SLNO	Soleno Therapeutics Inc	2019-11-19	667	57.31	38,226

Holding Weightings of Gwen A Melincoff

Gwen A Melincoff Form 4 Trading Tracker

According to the SEC Form 4 filings, Gwen A Melincoff has made a total of 1 transactions in Soleno Therapeutics Inc (SLNO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Soleno Therapeutics Inc is the acquisition of 667 shares on November 19, 2019, which cost Gwen A Melincoff around $15,400.

Insider Trading History of Gwen A Melincoff

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gwen A Melincoff Trading Performance

GuruFocus tracks the stock performance after each of Gwen A Melincoff's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gwen A Melincoff is 121.71%. GuruFocus also compares Gwen A Melincoff's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gwen A Melincoff within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gwen A Melincoff's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gwen A Melincoff

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	12.5
Relative Return to S&P 500(%)	9.77

Gwen A Melincoff Ownership Network

Ownership Network List of Gwen A Melincoff

No Data

Ownership Network Relation of Gwen A Melincoff

Gwen A Melincoff Owned Company Details

What does Collegium Pharmaceutical Inc do?

Who are the key executives at Collegium Pharmaceutical Inc?

Gwen A Melincoff is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP and Chief Medical Officer Thomas B Smith , EVP and General Counsel Shirley R. Kuhlmann , and EVP & Chief Financial Officer Tupper Colleen .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Gwen A Melincoff made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 198,212 shares made by Joseph Ciaffoni , a net sale of 88,809 shares made by Shirley R. Kuhlmann , and a net sale of 141,576 shares made by Scott Dreyer .

In summary, during the past 3 months, insiders sold 29,818 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 29,818 shares. During the past 18 months, 486,885 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 486,885 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

What does Soleno Therapeutics Inc do?

Who are the key executives at Soleno Therapeutics Inc?

Gwen A Melincoff is the director of Soleno Therapeutics Inc. Other key executives at Soleno Therapeutics Inc include See Remarks Patricia C Hirano , See Remarks Kristen Yen , and director & See Remarks Bhatnagar Anish .

Soleno Therapeutics Inc (SLNO) Insider Trades Summary

Over the past 18 months, Gwen A Melincoff made no insider transaction in Soleno Therapeutics Inc (SLNO). Other recent insider transactions involving Soleno Therapeutics Inc (SLNO) include a net sale of 479,373 shares made by Bhatnagar Anish , a net sale of 79,014 shares made by Kristen Yen , and a net sale of 47,490 shares made by Patricia C Hirano .

In summary, during the past 3 months, insiders sold 1,210,871 shares of Soleno Therapeutics Inc (SLNO) in total and bought 0 shares, with a net sale of 1,210,871 shares. During the past 18 months, 2,825,824 shares of Soleno Therapeutics Inc (SLNO) were sold and 1,210,087 shares were bought by its insiders, resulting in a net sale of 1,615,737 shares.

Soleno Therapeutics Inc (SLNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Soleno Therapeutics Inc Insider Transactions

No Available Data

What does Protalix BioTherapeutics Inc do?

Who are the key executives at Protalix BioTherapeutics Inc?

Gwen A Melincoff is the director of Protalix BioTherapeutics Inc. Other key executives at Protalix BioTherapeutics Inc include director & President and CEO Dror Bashan , 10 percent owner Dexcel Pharma Technologies Ltd. , and 10 percent owner Dan Oren .

Protalix BioTherapeutics Inc (PLX) Insider Trades Summary

Over the past 18 months, Gwen A Melincoff made no insider transaction in Protalix BioTherapeutics Inc (PLX). Other recent insider transactions involving Protalix BioTherapeutics Inc (PLX) include a net purchase of 64,516 shares made by Dror Bashan ,

In summary, during the past 3 months, insiders sold 0 shares of Protalix BioTherapeutics Inc (PLX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Protalix BioTherapeutics Inc (PLX) were sold and 64,516 shares were bought by its insiders, resulting in a net purchase of 64,516 shares.

Protalix BioTherapeutics Inc (PLX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protalix BioTherapeutics Inc Insider Transactions

No Available Data

What does Regado Biosciences Inc do?

Who are the key executives at Regado Biosciences Inc?

Gwen A Melincoff is the director of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Associates Domain , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .

Regado Biosciences Inc (RGDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Regado Biosciences Inc Insider Transactions

No Available Data

What does Gain Therapeutics Inc do?

Who are the key executives at Gain Therapeutics Inc?

Gwen A Melincoff is the director of Gain Therapeutics Inc. Other key executives at Gain Therapeutics Inc include Chief Operating Officer Matthias Alder , Chief Financial Officer Charles Evan Ballantyne , and Principal Accounting Officer Gianluca Fuggetta .

Gain Therapeutics Inc (GANX) Insider Trades Summary

Over the past 18 months, Gwen A Melincoff made no insider transaction in Gain Therapeutics Inc (GANX). Other recent insider transactions involving Gain Therapeutics Inc (GANX) include a net sale of 2,026 shares made by Matthias Alder , a net purchase of 50,000 shares made by Khalid Islam , and a net purchase of 30,000 shares made by Jeffrey Scott Riley .

In summary, during the past 3 months, insiders sold 0 shares of Gain Therapeutics Inc (GANX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,026 shares of Gain Therapeutics Inc (GANX) were sold and 111,400 shares were bought by its insiders, resulting in a net purchase of 109,374 shares.

Gain Therapeutics Inc (GANX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Gain Therapeutics Inc Insider Transactions

No Available Data

Gwen A Melincoff Mailing Address

Above is the net worth, insider trading, and ownership report for Gwen A Melincoff. You might contact Gwen A Melincoff via mailing address: C/o Tobira Therapeutics, Inc., 701 Gateway Boulevard, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.